PuSH - Publikationsserver des Helmholtz Zentrums München

Sahu, T.* ; Verma, H.K. ; Bhaskar, L.V.K.S.*

Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required.

World J. Virol. 11, 107-110 (2022)
Verlagsversion DOI PMC
Free journal
Creative Commons Lizenzvertrag
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Letter to the Editor
Korrespondenzautor
Schlagwörter Bacterial Co-infection ; Covid-19 ; Co-infection ; Fungal Co-infection
ISSN (print) / ISBN 2220-3249
e-ISSN 2220-3249
Zeitschrift World Journal of Virology
Quellenangaben Band: 11, Heft: 2, Seiten: 107-110 Artikelnummer: , Supplement: ,
Verlag Baishideng Publ.
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)